Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV).
Podjanee JittamalaWilliam H K SchillingJames A WatsonViravarn LuviraTanaya SiripoonThundon NgamprasertchaiPedro J AlmeidaManeerat EkkapongpisitCintia CruzJames J CallerySimon BoydOrawan AnunsittichaiMaliwan HongsuwanYutatirat SinghabootWatcharee PagornratRunch TuntipaiboontanaVaraporn KruabkonthoThatsanun NgernsengJaruwan TubprasertMohammad Yazid AbdadSrisuda KeayarsaWanassanan MadmaneeRenato S AguiarFranciele M SantosElizabeth M BattyPongtorn HanboonkunupakarnBorimas HanboonkunupakarnSakol SookpromeKittiyod PoovorawanMallika ImwongWalter R J TaylorVasin ChotivanichChunlanee SangketchonWiroj RuksakulKesinee ChotivanichSasithon PukrittayakameeArjen M DondorpNicholas P J DayMauro M TeixeiraWatcharapong PiyaphaneeWeerapong PhumratanaprapinNicholas J WhitePublished in: The Journal of infectious diseases (2023)
Parenteral remdesivir accelerates viral clearance in early symptomatic COVID-19. Pharmacometric assessment of therapeutics using the described method can rapidly and efficiently determine in vivo clinical efficacy.